title: [New medications; bevacizumab].
abstract: Bevacizumab is a humanised monoclonal antibody that targets vascular endothelial growth factor. By blocking the growth factor, bevacizumab inhibits the development of new blood vessels, which in turn inhibits the growth oftumours and metastases. Mean disease-free survival is prolonged in patients with metastatic colorectal carcinoma who are treated with bevacizumab. Evaluation of bevacizumab in other indications is underway.
authors.affiliation: Centre for Human Drug Research, Leiden. ac@chdr.nl
authors.forename: A F
authors.initials: AF
authors.lastname: Cohen
authors.forename: H
authors.initials: H
authors.lastname: van Bronswijk
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab